ALRN News and Press, Aileron Therapeutics Inc. From 06/29/22

Patients on ALRN-6924 were able to stay on treatment longer, completing more of the first 4 cycles of carboplatin/pemetrexed (93% of cycles on ALRN-6924 versus 78% on placebo); this imbalance between treatment arms may have introduced a bias against ALRN-6924 on the composite primary endp...

Aileron Therapeutics (NASDAQ:ALRN) said it treated the first patients in a phase 1b trial of ALRN-6924 to prevent chemotherapy induced toxicities. The Boston-based company is evaluating ALRN-6924 for preventing chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicitie...

Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities Trial is evaluating ALRN-6924 as a treatment to prevent chemotherapy-induced neutropenia, other bone marrow toxicities, and toxicities ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reduced focus on Covid-19 and less worries about interest rates should push many biotech stocks higher. vTv Therapeutics ( VTVT ) has strong positive catalysts in the medium term and the long term. Novavax ( ...

BOSTON, May 17, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Execu...

BOSTON, May 13, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will host a virtual KOL investor event on Thursday...

Taxanes, such as paclitaxel and docetaxel, cause severe and often permanent chemotherapy-induced hair loss (alopecia) New non-clinical data demonstrate proof of principle that ALRN-6924 can temporarily arrest the cell cycle in human scalp hair follicles and their stem cells ALRN...

Aileron Therapeutics press release (NASDAQ:ALRN): Q1 GAAP EPS of -$0.09 misses by $0.01. Cash and cash equivalents of $38.07M For further details see: Aileron Therapeutics GAAP EPS of -$0.09 misses by $0.01

On track to report interim results from Phase 1b clinical trial of ALRN-6924 in patients with advanced p53-mutated non-small cell lung cancer (NSCLC) in June 2022; topline results anticipated in 4Q 2022 On track to initiate Phase 1b clinical trial of ALRN-6924 in patients with p53-mut...

Mr. Zergebel brings over 20 years of industry experience, primarily focused in oncology, and broad expertise to help Aileron ensure operational excellence Aileron is advancing ALRN-6924 with the goal of delivering a chemoprotective agent for patients with p53-mutated cancer Clinic...